Abstract: This invention relates to a medicine for humans, and particularly to a pharmaceutical combination comprising Epidermal Growth Factor (EGF) and Growth Hormone secretagogue hexapeptide (GHRP) for use in preventing tissue damage due to blood flow suppression by enhancing tissue repair following ischemic damage. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is also useful in promoting cellular survival when tissue or organs are exposed to prolonged ischemic periods.

Abstract: A method for mixing a drilling fluid formulation that includes establishing a flow path for a base fluid, adding drilling fluid additives to the base fluid to create a mixture, aerating the mixture of base fluid and drilling fluid additives, and injecting a compressible driving fluid into the mixture of base fluid and drilling fluid additives to form a mixed drilling fluid is disclosed.

Abstract: This invention relates to human medicine, and particularly with a pharmaceutical combination made up with Epidermal Growth Factor (EGF) and a Growth Hormone secretagogue hexapeptide (GHRP); being useful to prevent tissue damages due to blood flow suppression as to enhance tissue repair following ischaemic damages. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is useful to promote cellular survival when tissues or organs are exposed to prolonged ischaemic periods.

Abstract: An apparatus and method for mixing materials such as reactants in a container which reduces or eliminates vortexing and swirling, improves mixing and eliminates degradation of the container and/or impeller comprises a container for holding liquids, a magnetic impeller coupled to a drive magnet located outside the container, where the impeller is suspended from a baffle assembly and located above the bottom of the container, a baffle assembly containing at least two vertical baffle elements with a horizontal cross member connecting the baffle elements, a portion or all of each of the baffle elements spaced from the wall of the container and a tube for providing liquid addition to the vicinity of the highly turbulent mixing around the impeller.